Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Haloperidol for agitation in dementia.

E Lonergan1, J Luxenberg, J Colford

  • 1Department of Medicine, UCSF School of Medicine, VA Medical Center, 4150 Clement St, San Francisco, California 94121, USA. tedlnrgn@aol.com

The Cochrane Database of Systematic Reviews
|June 22, 2002
PubMed
Summary

Haloperidol may help control aggression in agitated dementia patients but does not improve overall agitation. Routine use is not supported due to potential side effects and lack of broad efficacy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evidence supporting the use of a brief cognitive assessment in routine clinical assessment for psychosis.

Schizophrenia (Heidelberg, Germany)·2022
Same author

Deathbed wills: assessing testamentary capacity in the dying patient.

International psychogeriatrics·2013
Same author

The wills of older people: risk factors for undue influence.

International psychogeriatrics·2008
Same author

Antipsychotics for delirium.

The Cochrane database of systematic reviews·2007
Same author

Valproic acid for agitation in dementia.

The Cochrane database of systematic reviews·2004
Same author

Transcutaneous electrical nerve stimulation (TENS) for dementia.

The Cochrane database of systematic reviews·2003

Area of Science:

  • Geriatric Medicine
  • Psychopharmacology
  • Clinical Trials

Background:

  • Agitation affects up to 70% of dementia patients.
  • Haloperidol has been a long-standing treatment for agitation in dementia, but its efficacy is debated.
  • Previous reviews had limitations, necessitating a broader analysis.

Purpose of the Study:

  • To evaluate the evidence supporting the use of haloperidol for agitation in dementia patients.
  • To determine if haloperidol offers significant benefits over placebo in managing agitation.
  • To assess the safety and tolerability of haloperidol in this population.

Main Methods:

  • Conducted a systematic review of randomized, placebo-controlled trials.
  • Searched multiple medical databases including MEDLINE, EMBASE, PsycInfo, and CINAHL.

Related Experiment Videos

  • Included trials with concealed allocation and assessed dementia and agitation using standardized measures.

    • Main Results:

    • Haloperidol did not show significant improvement in overall agitation compared to placebo.
    • A decrease in aggression was observed in the haloperidol group.
    • No significant difference in dropout rates due to adverse effects was found between haloperidol and placebo groups.

    Conclusions:

    • Haloperidol may be effective for aggression but not other agitation symptoms in dementia.
    • Routine use of haloperidol for agitated dementia is not supported by current evidence.
    • Individualized treatment and monitoring for side effects are crucial when considering haloperidol for agitated dementia.